Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Growth in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 1,541,639 shares, a growth of 1,180.8% from the June 30th total of 120,361 shares. Currently, 14.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,865,720 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Avalon GloboCare Price Performance

The stock has a market cap of $4.05 million, a P/E ratio of -0.08 and a beta of -0.03. The company has a 50-day moving average of $0.32 and a 200-day moving average of $0.57. Avalon GloboCare has a twelve month low of $0.21 and a twelve month high of $4.74.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.